{
    "xml": "<topic id=\"PHP5306\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/daunorubicin\" basename=\"daunorubicin\" title=\"DAUNORUBICIN\">\n<title>DAUNORUBICIN</title>\n<body>\n<data name=\"vtmid\">35300007</data>\n<data name=\"vtmid\">422993007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_109608734\" title=\"Anthracyclines\">Anthracyclines</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP62803\" outputclass=\"indicationsAndDose\" rev=\"1.22\" parent=\"/drugs/daunorubicin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Acute myelogenous leukaemia</p>\n<p outputclass=\"therapeuticIndication\">Acute lymphocytic leukaemia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult local protocol).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Advanced AIDS-related Kaposi's sarcoma (liposomal formulation only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62967\" outputclass=\"contraindications\" rev=\"1.12\" parent=\"/drugs/daunorubicin\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Myocardial insufficiency</ph>; <ph outputclass=\"contraindication\">previous treatment with maximum cumulative doses of daunorubicin or other anthracycline</ph>; <ph outputclass=\"contraindication\">recent myocardial infarction</ph>; <ph outputclass=\"contraindication\">severe arrhythmia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63067\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/daunorubicin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Caution in handling&#8212;irritant to tissues</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62770\" outputclass=\"interactions\" rev=\"1.24\" parent=\"/drugs/daunorubicin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Caution is necessary with concomitant use of cardiotoxic drugs, or drugs that reduce cardiac contractility.</p>\n<p>Concomitant use with trastuzumab is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24&#8239;weeks. If trastuzumab needs to be used, cardiac function should be monitored closely.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62601\" outputclass=\"sideEffects\" rev=\"1.17\" parent=\"/drugs/daunorubicin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Cardiotoxicity</p>\n<p>All anthracycline antibiotics have been associated with varying degrees of cardiac toxicity&#8212;this may be idiosyncratic and reversible, but is commonly related to total cumulative dose and is irreversible</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63042\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/daunorubicin\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62737\" outputclass=\"pregnancy\" parent=\"/drugs/daunorubicin\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (teratogenic and carcinogenic in <i>animal</i> studies).</p>\n</sectiondiv>\n<sectiondiv>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63097\" outputclass=\"breastFeeding\" parent=\"/drugs/daunorubicin\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62861\" outputclass=\"hepaticImpairment\" parent=\"/drugs/daunorubicin\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose according to serum bilirubin concentration&#8212;consult local protocol for details.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62662\" outputclass=\"renalImpairment\" parent=\"/drugs/daunorubicin\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose by 25% if serum creatinine 105&#8211;265&#8239;micromol/litre.</p>\n<p>Reduce dose by 50% if serum creatinine greater than 265&#8239;micromol/litre.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62576\" outputclass=\"monitoringRequirements\" parent=\"/drugs/daunorubicin\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Cardiac monitoring essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5306-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/daunorubicin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76279\" title=\"Powder for solution for infusion\" namespace=\"/drugs/daunorubicin/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76273\" title=\"Emulsion for infusion\" namespace=\"/drugs/daunorubicin/emulsion-for-infusion\">Emulsion for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78537\" namespace=\"/treatment-summaries/cytotoxic-drugs\" title=\"Cytotoxic drugs\" count=\"2\" rel=\"backlink\">Cytotoxic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76279\" namespace=\"/drugs/daunorubicin/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76273\" namespace=\"/drugs/daunorubicin/emulsion-for-infusion\" title=\"Emulsion for infusion\" count=\"1\" rel=\"link\">Emulsion for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5306",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/daunorubicin",
    "basename": "daunorubicin",
    "title": "DAUNORUBICIN",
    "vtmid": "422993007",
    "drugClassification": [
        "Anthracyclines"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Acute myelogenous leukaemia",
                        "html": "Acute myelogenous leukaemia"
                    },
                    {
                        "textContent": "Acute lymphocytic leukaemia",
                        "html": "Acute lymphocytic leukaemia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult local protocol).",
                        "html": "<p>(consult local protocol).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Advanced AIDS-related Kaposi's sarcoma (liposomal formulation only)",
                        "html": "Advanced AIDS-related Kaposi's sarcoma (liposomal formulation only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Myocardial insufficiency",
                "html": "Myocardial insufficiency"
            },
            {
                "type": "contraindications",
                "textContent": "previous treatment with maximum cumulative doses of daunorubicin or other anthracycline",
                "html": "previous treatment with maximum cumulative doses of daunorubicin or other anthracycline"
            },
            {
                "type": "contraindications",
                "textContent": "recent myocardial infarction",
                "html": "recent myocardial infarction"
            },
            {
                "type": "contraindications",
                "textContent": "severe arrhythmia",
                "html": "severe arrhythmia"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Caution in handling&#8212;irritant to tissues",
                "html": "Caution in handling&#8212;irritant to tissues"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Caution is necessary with concomitant use of cardiotoxic drugs, or drugs that reduce cardiac contractility.\n\nConcomitant use with trastuzumab is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If trastuzumab needs to be used, cardiac function should be monitored closely.",
                "html": "<p>Caution is necessary with concomitant use of cardiotoxic drugs, or drugs that reduce cardiac contractility.</p><p>Concomitant use with trastuzumab is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24&#8239;weeks. If trastuzumab needs to be used, cardiac function should be monitored closely.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Cardiotoxicity",
                "textContent": "All anthracycline antibiotics have been associated with varying degrees of cardiac toxicity&#8212;this may be idiosyncratic and reversible, but is commonly related to total cumulative dose and is irreversible",
                "html": "<p>All anthracycline antibiotics have been associated with varying degrees of cardiac toxicity&#8212;this may be idiosyncratic and reversible, but is commonly related to total cumulative dose and is irreversible</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (teratogenic and carcinogenic in animal studies).",
                "html": "<p>Avoid (teratogenic and carcinogenic in <i>animal</i> studies).</p>"
            },
            {
                "type": "generalInformation",
                "textContent": "Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose according to serum bilirubin concentration&#8212;consult local protocol for details.",
                "html": "<p>Reduce dose according to serum bilirubin concentration&#8212;consult local protocol for details.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose by 25% if serum creatinine 105&#8211;265 micromol/litre.\n\nReduce dose by 50% if serum creatinine greater than 265 micromol/litre.",
                "html": "<p>Reduce dose by 25% if serum creatinine 105&#8211;265&#8239;micromol/litre.</p><p>Reduce dose by 50% if serum creatinine greater than 265&#8239;micromol/litre.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Cardiac monitoring essential.",
                "html": "<p>Cardiac monitoring essential.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76279",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76273",
                "label": "Emulsion for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78537",
                "label": "Cytotoxic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76279",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76273",
                "label": "Emulsion for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}